@article{afbab7931e0d41dcb60743d20ad831e6,
title = "Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?",
author = "Antonarakis, {Emmanuel S.}",
note = "Funding Information: I am a paid consultant or advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck. I have received research funding to my institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck. I am the co-inventor of a biomarker technology that has been licensed to Qiagen. This work was partially supported by the National Institutes of Health (P30 CA006973) and the US Department of Defense (W81XWH-16-PCRP-CCRSA).",
year = "2018",
month = jul,
doi = "10.1016/S1470-2045(18)30409-1",
language = "English (US)",
volume = "19",
pages = "860--861",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",
}